RxDoctor Payments Data

Elizabeth Turnage, MD

Family Medicine · Waco, TXNPI 1154393890

Payments from drug & device makers

$10,284in general payments, 2019–2025

Across 649 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$596
  • Pfizer$520
  • GSK$518
  • Astellas Pharma US Inc$433
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$10,22799%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,284 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$109,993
Medicare patients
206
Services billed
2,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide94$147,822
OzempicSemaglutide104$124,656
FarxigaDapagliflozin Propanediol108$117,963
EliquisApixaban52$52,267
JardianceEmpagliflozin29$31,088
TrulicityDulaglutide19$30,377
LinzessLinaclotide24$17,021
Fluticasone-SalmeterolFluticasone Propion/Salmeterol64$14,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,580
MyrbetriqMirabegron11$13,253
XareltoRivaroxaban12$9,649
Irbesartan347$8,645
Rosuvastatin Calcium453$8,174
NamzaricMemantine Hcl/Donepezil Hcl13$7,908
Combivent RespimatIpratropium/Albuterol Sulfate12$6,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$414$178,199113 claims
Novo NordiskOzempic$1,073$124,656104 claims
AstraZenecaFarxiga$596$117,963108 claims
PfizerEliquis$520$52,26752 claims
Boehringer IngelheimJardiance, Combivent Respimat$378$37,29641 claims
AbbVieLinzess, Namzaric, Synthroid$1,444$26,72764 claims
GSKTrelegy Ellipta$518$13,58016 claims
Astellas Pharma US IncMyrbetriq$433$13,25311 claims
Johnson & JohnsonXarelto$124$9,64912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →